Does E2B(R3) Impact Companies With No Safety Reporting System?

Accelerate Clinical Trials With AI and Real-Time Data Collaboration

Discover a unified clinical data review and collaboration solution that optimizes the integration and review of complex, ever-changing clinical data.

Get the Guide

The issue is not the type of system used to collect adverse event data, but rather how the data is submitted to the FDA, EMA, and MHLW. If an organization is using spreadsheets to collect safety data or is unable to transmit data via E2B, it will have to report the data via a web-based tool, such as the FDA’s WebTrader or EMA’s EVWEB.

To learn about E2B(R3), the impact it is likely to have on drug safety business processes, and some ideas for how to move forward, fill out the form below or click here.